Literature DB >> 33676467

Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis.

Jianping Zhao1, Yao Chen1, Jingjing Wang2, Jian Wang3, Ying Wang4, Songshan Chai1, Yuxin Zhang1, Xiaoping Chen5, Wanguang Zhang6.   

Abstract

BACKGROUND: Cumulating evidence indicates that the systemic inflammatory response (SIR) plays a crucial role in the prognosis of various cancers. We aimed to generate a preoperative risk grade (PRG) by integrating SIR markers to preoperatively predict the long-term prognosis of intrahepatic cholangiocarcinoma (ICC).
METHODS: 468 consecutive ICC patients who underwent hepatectomy between 2010 and 2017 were enrolled. The PRG and a nomogram were generated and their predictive accuracy was evaluated.
RESULTS: The PRG consisted of two non-tumor-specific SIR markers platelet-to-lymphocyte ratio (PLR) and albumin (ALB), which were both the independent predictors of overall survival (OS). Multivariate analysis showed that the PRG was significantly associated with OS (PRG = 1: hazard ratio (HR) = 3.800, p < 0.001; PRG = 2: HR = 7.585, p < 0.001). The C-index of the PRG for predicting survival was 0.685 (95% CI 0.655 to 0.716), which was statistically higher than that of the following systems: American Joint Committee on Cancer (AJCC) 8th edition (C-index 0.645), Liver Cancer Study Group of Japan (LCSGJ) (C-index 0.644) and Okabayashi (C-index 0.633) (p < 0.05). Besides, the C-index of the nomogram only consisting of the tumor-specific factors (serum carcinoembryonic antigen, carbohydrate antigen 19-9, tumor number) could be improved to 0.737 (95% CI 0.062-0.768) from 0.625 (95% CI 0.585-0.665) when the PRG was incorporated (p < 0.001).
CONCLUSIONS: The PRG integrating two non-tumor-specific SIR markers PLR and ALB was a novel method to preoperative predicting the prognosis of ICC.

Entities:  

Keywords:  Albumin and prognosis; Intrahepatic cholangiocarcinoma; Platelet-to-lymphocyte ratio; Systemic inflammatory response

Year:  2021        PMID: 33676467     DOI: 10.1186/s12893-020-00954-x

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.102


  48 in total

1.  Cancer: Inflaming metastasis.

Authors:  Alberto Mantovani
Journal:  Nature       Date:  2009-01-01       Impact factor: 49.962

2.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

3.  Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma.

Authors:  Kazunari Sasaki; Georgios A Margonis; Nikolaos Andreatos; Fabio Bagante; Matthew Weiss; Carlotta Barbon; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Federico N Aucejo; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2017-12-21       Impact factor: 6.113

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma.

Authors:  Stefan Buettner; Gaya Spolverato; Charles W Kimbrough; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Matthew Weiss; Todd W Bauer; Feng Shen; George A Poultsides; J Wallis Marsh; Jan N M IJzermans; Bas Groot Koerkamp; Timothy M Pawlik
Journal:  Surgery       Date:  2018-06-11       Impact factor: 3.982

6.  A proposed staging system for intrahepatic cholangiocarcinoma.

Authors:  Hari Nathan; Thomas A Aloia; Jean-Nicolas Vauthey; Eddie K Abdalla; Andrew X Zhu; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2008-11-06       Impact factor: 5.344

Review 7.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

8.  Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

Authors:  Itaru Endo; Mithat Gonen; Adam C Yopp; Kimberly M Dalal; Qin Zhou; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Lawrence Schwartz; Nancy Kemeny; Eileen O'Reilly; Ghassan K Abou-Alfa; Hiroshi Shimada; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg       Date:  2008-07       Impact factor: 12.969

9.  Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.

Authors:  Yizhou Wang; Jun Li; Yong Xia; Renyan Gong; Kui Wang; Zhenlin Yan; Xuying Wan; Guanghua Liu; Dong Wu; Lehua Shi; Wanyee Lau; Mengchao Wu; Feng Shen
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

Review 10.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

View more
  2 in total

1.  The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Dong Liu; Lara R Heij; Zoltan Czigany; Edgar Dahl; Marcel den Dulk; Sven A Lang; Tom F Ulmer; Ulf P Neumann; Jan Bednarsch
Journal:  Sci Rep       Date:  2022-07-25       Impact factor: 4.996

Review 2.  The Value of Platelet-to-Lymphocyte Ratio as a Prognostic Marker in Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Dong Liu; Zoltan Czigany; Lara R Heij; Stefan A W Bouwense; Ronald van Dam; Sven A Lang; Tom F Ulmer; Ulf P Neumann; Jan Bednarsch
Journal:  Cancers (Basel)       Date:  2022-01-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.